Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 2

Status

Active not recruiting 2Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 4NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 2

Conditions

Lymphoma, Large B-Cell, Diffuse 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Prostatic Neoplasms 7Lymphoma 5Burkitt Lymphoma 5Neoplasms 4Leukemia, Biphenotypic, Acute 4Ovarian Neoplasms 3Lymphoma, Follicular 3Hodgkin Disease 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Metastatic Castration-resistant Prostate Cancer 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Leukemia 2Endometrial Neoplasms 2Down Syndrome 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Neoplasm Metastasis 1Myasthenia Gravis 1Lymphoma, T-Cell, Peripheral 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Immunoblastic Lymphadenopathy 1Heart Failure 1Enteropathy-Associated T-Cell Lymphoma 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Cyclophosphamide 61Rituximab 50fludarabine 34Prednisone 33Doxorubicin 28Biopsy 26Vincristine 25Specimen Handling 22Magnetic Resonance Spectroscopy 20Bendamustine Hydrochloride 19pembrolizumab 16Lenalidomide 16obinutuzumab 14fludarabine phosphate 14Etoposide 14venetoclax 13Tacrolimus 11Mycophenolic Acid 10Melphalan 10Dexamethasone 10zanubrutinib 9ibrutinib 9acalabrutinib 9Radiotherapy 9Gemcitabine 9Cytarabine 9Busulfan 9Whole-Body Irradiation 8Mesna 8Filgrastim 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Lymphoma × Prednisolone × 1 year × Clear all
NCT04546620 2026-04-30

REMoDL-A

University Hospital Southampton NHS Foundation Trust

Phase 2 Active not recruiting
453 enrolled
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

NCT05800366 2026-03-05

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Recruiting
41 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03117751 2025-12-05

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

St. Jude Children's Research Hospital

Phase 2/3 Active not recruiting
790 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡